Retagliptin

Retagliptin is a DPP-4 inhibitor studied for the treatment of type 2 diabetes.

Uses your system voice; voice and rate in settings.

Snapshot

≈ 1 min read

Names in other languages

No names in other languages are held for this entry yet.

Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.

Retagliptin is a DPP-4 inhibitor studied for the treatment of type 2 diabetes. In 2023, it was approved in China by the National Medical Products Administration for blood glucose control for adult patients with type 2 diabetes.

Text derived from https://en.wikipedia.org/w/index.php?oldid=1370837440 under CC BY-SA 4.0; modifications have been made.

Sources cited in this revision

2 named source(s) extracted from the cited revision. A source with no author is shown by its publication; nothing is invented.